New Blood Preservation Technologies Have Been Developed at the Dubna Nanocenter
The Dubna Nanocenter has developed new blood preservation technologies, the press service of the Ministry of Investment and Innovation of the Moscow Region has reported. The Bioconservanty start-up received the terms of reference for the development of blood glucose preservatives from Invitro, the largest medical laboratory diagnostic network in the Russian market. The startup team of a resident of the Dubna SEZ has met the challenge.
The Bioconservanty start-up, part of the International Innovation Nanotechnology Center, is aimed at developing and implementing biofluid analysis preservation technology in industrial production to stabilize blood glucose levels after the analysis is collected. This will allow more effective preservation of the initial composition of blood tests, bringing it closer to the real values in the human body.
“Blood sugar is important in diagnosing various diseases, especially diabetes. Laboratory glucose tests help to assess this indicator. Doctors pay great attention to controlling blood glucose levels and maintaining its initial values. This can be done through the long-term preservation of blood tests,” explained Sergey Tokarev, Head of the Bioconservanty project.
Today, there are two main technologies to avoid the breakdown of glucose in blood tests. The first one is freezing, an expensive and difficult-to-transport method. In the second, lithium heparin and sodium fluoride are used, but the decay time is too short.
The experts of the Bioconservanty project proposed to replace sodium fluoride with other substances and proved that the shelf life without loss of glucose could be increased up to 48 hours. The research is ongoing. The company plans not only to increase the preservation period but also to make the solution suitable for testing other biofluids.